An industry for healthy lives

Vaccines Europe represents all the major vaccine companies operating in Europe which undertake 79% of their global production and more than 50% of their global research projects in the region.

News & press releases

Annual Health & Economic Benefits of Influenza Vaccination

2015 12 07 Written by Vaccines Europe

Influenza is a serious infectious disease with potentially serious consequences. Every year in the EU, the ECDC estimates that on average 40,000 premature deaths occur due to seasonal influenza. Globally this figure rises to 500,000 (WHO). Nevertheless, influenza can be prevented, achieving important health and economic benefits. These benefits can be optimised if the EU Member States were to reach the 75% vaccination coverage target agreed upon by the Council for the elderly and at risk groups. Read more…

Additional Research Confirms the Absence of a link between the Measles Mumps Rubella (MMR) Vaccine and Autism

2015 10 05 Written by Vaccines Europe

Last week, yet another study published in the Proceedings of the National Academy of Sciences (PNAS) further discredited a link previously claimed between the Measles Mumps Rubella (MMR) vaccine and autism in children. This time, the funding for the research came from a US-based organisation involved in the anti-vaccination movement. The study was conducted by scientists from the University of Texas Southwestern School of Medicine, the University of Washington, the Johnson Center for Child Health & Development and other research institutions. Read more…

Vaccines Europe is recruiting a Regulatory and Scientific Affairs Manager

2015 09 11 Written by Vaccines Europe


Job Description: 
The person appointed will be based in the Vaccines Europe/EFPIA Office in Brussels, Belgium and will report directly to the Vaccines Europe Executive Director. Read more…

Page 1 of 1612345...10...Last »